GDTC earnings date and last-quarter result: next report 2026-11-13, P/E -3.06. Updated 2026-07-23.
CytoMed Therapeutics (GDTC) Research Hub
CytoMed Therapeutics (GDTC) trades on NASDAQ, SG in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.9262 USD (+0.78%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.06, market cap 0.01B. This hub links to the full technical, earnings and options research available for GDTC.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, SG |
| Last close | 0.9262 USD (+0.78%) |
| 52-week range | 0.71 USD – 1.21 USD |
| Trend regime | Range |
| 14-day RSI | 49.6 (Neutral) |
| Trailing P/E | -3.06 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-11-13 |
Available research for GDTC
Covered Call on GDTC: how it works, illustrative setup around the real 0.9262 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GDTC: how it works, illustrative setup around the real 0.9262 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GDTC: how it works, illustrative setup around the real 0.9262 USD price, max profit/loss, breakeven and when to use it. Educational.
GDTC technical analysis: range, last 0.9262 USD, RSI 49.6, 52w range 0.71 USD–1.21 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GDTC in?
CytoMed Therapeutics (GDTC) is classified under Healthcare (Biotechnology), listed on NASDAQ, SG.
Is GDTC in an uptrend or downtrend?
As of 2026-10-26, GDTC is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GDTC's trailing P/E ratio?
GDTC's trailing P/E is -3.06, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does GDTC next report earnings?
GDTC is next scheduled to report earnings on 2026-11-13.